Literature DB >> 20443156

Testicular cancer: when less is more.

Lance C Pagliaro1.   

Abstract

Clinical stage I testicular cancer is highly curable. The treatment options include adjuvant chemotherapy or surveillance for most patients, radiotherapy for seminoma, and retroperitoneal lymph node dissection for selected patients with nonseminomatous germ cell tumors. This review discusses the decision points with emphasis on the advantages and disadvantages of each management option.

Entities:  

Mesh：

Year:  2010        PMID： 20443156     DOI： 10.1007/s11912-010-0105-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  24 in total

1.  Vox populi: Using community-based studies to determine best management of early-stage nonseminoma.

Authors:  Craig R Nichols; Christian Kollmannsberger
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

2.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

3.  Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage i nonseminomatous germ cell tumor.

Authors:  U E Studer; F C Burkhard; R W Sonntag
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

4.  Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

Authors:  Jorge Aparicio; José R Germà; Xavier García del Muro; Pablo Maroto; José A Arranz; Alberto Sáenz; Agustín Barnadas; Joan Dorca; Josep Gumà; David Olmos; Romá Bastús; Joan Carles; Daniel Almenar; Miguel Sánchez; Luis Paz-Ares; Juan J Satrústegui; Begoña Mellado; Ana Balil; Marta López-Brea; Alfredo Sánchez
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

Review 5.  Controversies in the management of clinical stage I testis cancer.

Authors:  Ronald de Wit; Karim Fizazi
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

6.  Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma.

Authors:  T A Buchholz; T L Walden; B R Prestidge
Journal:  Cancer       Date:  1998-03-15       Impact factor: 6.860

7.  Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma.

Authors:  N N Sharda; T J Kinsella; M A Ritter
Journal:  J Clin Oncol       Date:  1996-11       Impact factor: 44.544

8.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

9.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

10.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

Authors:  M H Cullen; S P Stenning; M C Parkinson; S D Fossa; S B Kaye; A H Horwich; S J Harland; M V Williams; R Jakes
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.